Treatment of Peanut Allergy.

Abstract

1. Amy Burris, MD*,† 2. Theresa Bingemann, MD*,† 1. *Department of Medicine: Allergy, Immunology, and Rheumatology and 2. †Division of Pediatric Allergy and Immunology, University of Rochester Medical Center, Rochester, NY Peanut allergy (PA) affects 0.5% to 2% of children and is often a persistent condition that poses the risk of life-threatening reactions on exposure to peanut. It is the most common food allergy to cause anaphylaxis and death. Because allergy testing does not predict the severity of reactions, it is imperative that peanut-allergic children have access to epinephrine autoinjectors at all times. Although cutaneous reactions, including generalized urticaria, angioedema, and atopic dermatitis, are the most common, anaphylaxis accounts for more than one-third of reactions. Recently, research has focused on prevention strategies for PA. In high-risk infants, early introduction of peanut at younger than 11 months of age plays a crucial role in preventing PA. Conversely, avoidance of peanut is associated with increased risk of PA. Guidelines recommend early introduction of peanut to infants with no eczema or mild to moderate eczema. Infants with severe eczema should be promptly referred to an allergist for evaluation of peanut sensitization before introduction. Disruption of the skin barrier, as with eczema, plays a role in the development of food allergy. Transcutaneous exposure of food allergens may promote allergic sensitization, whereas allergen exposure through the gut may promote tolerance. Studies show that increased environmental peanut exposure leads to increased risk of PA, especially in children with eczema. Aggressive emollient therapy early in life may decrease the risk of developing eczema. Studies examining the role of early emollient therapy and development of food allergy are ongoing. The cross-reactivity between peanut allergens and environmental allergens means that apparent sensitization to peanut does not necessarily …